Various small-molecule inhibitors and monoclonal antibodies that recognize c-Met have undergone evaluation in preclinical studies, such as capmatinib, a highly potent and selective c-Met inhibitor recently approved by the FDA for treating metastatic non-small-cell lung cancer [34]. Here, MET is linked to non-small cell lung carcinoma.